Strategy of SAKIGAKE as a Package

～Lead the world through the practical application of innovative medical products～

Promote the strategy package facilitating all the process from R&D, clinical research/trials, pre- and post- marketing safety, insurance coverage, through globalization of innovative products which are to be put into practical use. Specifically, this package is targeting innovative pharmaceuticals/medical devices/regenerative medicine which can cure serious illnesses (such as rare diseases/cancer etc.) unless established therapy is available.

Prioritized Policy I — ***SAKIGAKE***

Prioritized Policy II — **Scheme to rapid authorization of unapproved drug**

Pre-Clinical Research → **Clinical Research /Trial** → **Approval** → **NHI* Price Listing** → **facilitate the environment for industry activities** → **International Deployment**

*:National Health Insurance

Accelerate R&D through supporting each stage

- Coalition between "Network for Drug Discovery" and "Pharmaceutical Affairs Consultation on Research and Development (R&D) Strategy"
- Support of Drug-Repositioning (DR) and development of off-label use
- Development of safety assessment technique for using iPS derived cells followed by international standardization
- R&D through public-private joint project
- High-quality clinical trials by Clinical Trial Core Hospital・NC and coalition with research group for rare diseases
- Support for orphan drug R&D
  Support for ultra-orphan through the R&D to Early designation
- Support for Drug Development through Medical Information and Communication Technology (MICT)
  - DB of Medical Information
  - Rapid and effective Clinical Trials
  - Incorporation into review for approval
- Analysis by Modeling and Simulation (M&S) conducted by PMDA
- Utilizing "Pre-application Consultation"
- Strengthening measures on post-marketing safety
  Development of system of patient registry
  Research on biomarker
- Improve the predictability of NHI drug price
  - Discussion on Premium to promote the development of new drugs and to eliminate off-label use
- Strengthening industry competitiveness
  - tax incentive
  - HR Development
- Support for SME and venture
  - Discussion on funding system for review user fee to be implemented
- Utilization of the data from clinical research of rare disease / cancer for post-marketing surveillance
- Mutual understanding of the process from R&D to approval with the trading partner, to promote export

Strengthen the structure of PMDA (consultation, review, safety measures in terms of quality and quantity)

Promotion of Regulatory Science (Developing guidelines/assessment for the state-of-the-art technology)

SAKIGAKE Designation System

SAKIGAKE is a system to put into practice innovative medicines/medical devices/regenerative medicines initially developed by Japan.

Designation Criteria

Medical products for diseases in urgent need of innovative therapy which may satisfy the following two conditions:

1. Having firstly developed in Japan and planned an application for approvals (desired to have PMDA consultation from the beginning of R&D)
2. Prominent effectiveness (i.e. radical improvement compared to existing therapy), can be expected based on the data of mechanism of action, non-clinical study and early phase of clinical trials (phase I to II)

Designation Advantage

: To shorten the time to approval

: To facilitate R&D

①Prioritized Consultation
[Waiting time: 2 months→1 month]
Shortening a waiting time for a clinical trial consultation from the submission of materials.

② Substantial Pre-application Consultation
[de facto review before application]
- Encouraging Consultation
- Accepting materials in English

③Prioritized Review
[12 months → 6 months]
Targeting total reviewing time: 6 months
* Accept the result of phase III study after the application on a case-by-case basis to shorten the time from R&D to approval

④Review Partner
[PMDA manager as a concierge]
Assign a manager as a concierge to take on overall management for the whole process toward approval including conformity assurance, quality management, safety measures, and reviewing application

⑤Substantial Post-Marketing Safety Measures
[Extension of re-examination period]
Strengthening post-marketing safety measures such as extension of re-examination period after approvals well as facilitating coalition with scientific societies, and global information dissemination.

Designation Procedure

1. **Option 1:** Application is to be submitted to Evaluation and Licensing Division (ELD) and to be reviewed by PMDA. The result of designation is to be notified within 60 days.
2. **Option 2:** ELD is to approach a potential applicant. The result of designation is to be notified within 30 days after the submission, if agreed by the applicant.

General Timeframe of *SAKIGAKE*



Scheme for Rapid Authorization of Unapproved Drug

Expand the scope of the Council on Unapproved Drug / Off-label Use to the products unapproved in EU/US, when satisfying certain conditions. Through the cooperation with industry on R&D for the products, lead the world in the practical use of innovative pharmaceuticals for life threatening rare/serious diseases.

Facilitate the environment for industries and support its R&D through **proactive conduct of clinical trials or Advanced Medical Care at Clinical Trials Core Hospitals, and National Center for Advanced Medical Technology** for products which have difficulty to make matching the data with company developing the product.

Unapproved drug /Off-label Use
(currently limited only to products approved in EU or US)

Accept and evaluate the as needed

Expand the current scope to products unapproved in EU/US if they satisfy one of the following conditions

① **Conducting/finalizing phase III study in Japan**
② **Promising calinical data shown in public domain such as a paper in scientific journals**
③ **Achievement in Advanced Medical Care B**

Evaluation committee on unapproved or off-labeled drugs with high medical needs

【Basic Scheme】(Almost all products fall into the scheme)

Request on a company / Public recruiting of company for R&D

Clinical Trial to be conducted by company

Submission of Application for Approval

【Where it takes time for matching due to R&D carried out overseas, etc.】

Clinical trials / Advanced Medical Care to be conducted at Clinical Trials Core Hospitals / National Center for Advanced Medical Technology to accumulate data enough for application

※Support the company for its R&D
※Utilize PMDA's Pharmaceutical Affairs Consultation on Research and Development (R&D) Strategy

Company conducting R&D